Novel nano-biomaterials for inhibition of respiratory syncytial virus by Joshi, S. et al.
Joshi, S. and Kirby, D. and Perrie, Y. and Singh, S. R. (2017) Novel nano-
biomaterials for inhibition of respiratory syncytial virus. In: Biotech, 
Biomaterials and Biomedical. TechConnect, California, pp. 75-78. ISBN 
9780998878201 , 
This version is available at https://strathprints.strath.ac.uk/63285/
Strathprints is  designed  to  allow  users  to  access  the  research  output  of  the  University  of 
Strathclyde. Unless otherwise explicitly stated on the manuscript, Copyright © and Moral Rights 
for the papers on this site are retained by the individual authors and/or other copyright owners. 
Please check the manuscript for details of any other licences that may have been applied. You 
may  not  engage  in  further  distribution  of  the  material  for  any  profitmaking  activities  or  any 
commercial gain. You may freely distribute both the url (https://strathprints.strath.ac.uk/) and the 
content of this paper for research or private study, educational, or not-for-profit purposes without 
prior permission or charge. 
Any correspondence concerning this service should be sent to the Strathprints administrator: 
strathprints@strath.ac.uk
The Strathprints institutional repository (https://strathprints.strath.ac.uk) is a digital archive of University of Strathclyde research 
outputs. It has been developed to disseminate open access research outputs, expose data about those outputs, and enable the 
management and persistent access to Strathclyde's intellectual output.
Novel Nano-biomaterials for Inhibition of Respiratory Syncytial Virus 
Sameer Joshi1, Daniel Kirby2, Yvonne Perrie3 Shree R. Singh1 
 
1Center for NanoBiotechnology Research, Alabama State University, Montgomery, Alabama, USA.  
2Aston Pharmacy School, Aston University, Birmingham, UK. 
3Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK. 
E-mail: s_ndds@hotmail.com 
 
ABSTRACT 
 
Respiratory syncytial virus (RSV) infection is a major 
concern for the population across all age groups and it is the 
single serotype with two major antigenic subgroups 
circulating together but one leads [1]. Considering 
published outcomes related to treatment, as well as the 
impact of RSV on global healthcare, a promising treatment 
or vaccine development remains a priority.  The potential of 
liposomes as  a carrier of active pharmacological agents 
was described decades ago [2-4], whilst liposomes have 
attracted much attention for their ability to carry antigens as 
well as immunomodulators [5]. Therefore, the work in this 
paper was aimed to prepare liposomes < 100 nm using thin 
film hydration followed by sonication, to effectively 
conjugate the anti-RSV peptide RF-482 and investigate the 
efficiency the liposomal formulation in presence and 
absence peptide RF-482 to inhibit RSV spread. 
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1 INTRODUCTION 
 
It was reported that gold nanoparticles (GNPs) can be 
functionalized with nucleic acid, antibodies, drugs as well 
as with peptides and these functionalized GNPs then can be 
applied in diagnosis of treatment of RSV infection [6]. Use 
of GNPs functionalized with anti RSV peptide RF-482 to 
inhibit RSV is a patented system [7]. Based on these 
findings and considering the nature of peptide RF-482, the 
liposomes were considered as alternative delivery system to 
deliver peptide RF-482. The peptide was expected to be 
ecapsulated or adsorbed on the surface of liposomes and 
bring same or better RSV inhibition compared to GNPs. 
The genome of RSV codes immunogenic proteins, 
which creates scope for DNA vaccines, subunit vaccines 
and nano vaccines [8]. These vaccines possibly designed as 
carrier based vaccine using nanoparticulate systems  such 
as liposomes, that expresses adjuvant action by enhanced 
antigen delivery or inducing innate immune responses [9]. 
The liposomes were prepared using the conventional thin 
film hydration method with and without peptide RF-482.  
The system was tested for peptide loading capacity and 
RSV inhibition. 
 
 
2 MATERIALS AND METHODS 
 
2.1 Materials 
1,2-disteroylphosphatidylcholine (DSPC) was 
purchased from Avanti Polar Lipids, Inc. (Alabaster, AL).  
Cholesterol was from Sigma-Aldrich Company Ltd. (Poole, 
UK) was purchased from Sigma-Aldrich Co (St Louis, MO, 
USA). The peptide RF-482 was purchased from Bachem 
Americas Inc., Santa Clara, CA, USA. Human epithelial 
type-2 (HEP-2) cells purcahsed from American Type 
Culture Collection (ATCC®, Manassas, VA, USA), were 
used to study the viral infection and inhibition. 
 
2.2 Functionlization of liposomes 
       The fusion peptide RF-482 is a small as well as heat 
sensitive. Therefore, a slight modification was done in the 
conventional thin film hydration method (Figure 2.2), 
where the protein was added post sonication when small 
unilamellar vesicles (SUV) were obtained and not added to 
the hydration buffer in spite of the hydrophilic nature of the 
protein. Briefly, a predetermined concentration of protein 
was added to the SUV suspension and mounted on a shaker 
for 30 minutes. This was done to facilitate the fusion of 
protein on to the liposomal surface. 
       
Figure 1 Illustration of thin film hydration based SUV 
production and loading of fusion protein RF-482. 
 
 
3 RESULTS AND DISCUSSION 
 
3.1 Confirmation of functionalization  
 Characterization of size of SUV was performed using 
dynamic light scattering (Malvern Zetasizer Nano-ZS) and 
the surface charges were studied using laser doppler 
velocimetry (Malvern Zetasizer Nano-ZS). RF-482 is a very 
small peptide and, therefore, a slight increase in the size of 
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liposomes can be expected to confirm the conjugation. 
There is a slight change in the size of liposomes (91.78 ± 
0.3 nm (PDI 0.2 ± 0.01) and 96.91 ± 0.6 nm (PDI 0.19 ± 
0.03) before and after conjugation, respectively). Because 
DSPC is a neutral lipid, there was no observed change in 
the  zeta potential due to conjugation of RF-482 (-9.9 ± 1 
mv and -12.2 ± 1.3 mv before and after conjugation, 
respectively) (Figure 2). 
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PDI = 0.19 ±0.03
PDI = 0.2 ± 0.01
Size= 91.78 nm ±0.3
Size=  96.91 nm ± 0.6
ZP= -9.98 mV ±1.0
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Before Conjugation
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Figure 2 DLS measurement of liposomes before and after 
RF-482conjugation. (n=3 ±SD). 
 
           The first and most supportive evidence of 
association of peptide with liposome was observed when 
FITC labelled peptide RF-482 was used for the conjugation. 
After the separation of non-conjugated peptide, the 
liposomal suspension was dried, covered with 
phosphotungstic acid for better resolution and observed 
under the fluorescence microscope. Imaging at low and 
high maginification shows the presence of peptide suggests 
the association of peptide RF-482 with liposomes (Figure 
3).  
 
 
Figure 3 Fluorescence microscopy analysis liposomes 
conjugated with FITC labelled peptide RF-482 (Green). 
10X and 40X magnification. 
 
Subsequently after the fluorescence imaging, the empty 
liposomes and the peptide conjugated liposomes were 
imaged under TEM. Association  of protein was again 
indicated  by a cloudy environment observed around the 
liposomes and a change in morphology (Figure 4b), that 
was not observed in the case of empty liposomes (Figure 
4a). 
 
 
Figure 4 Transmission electron microscopy analysis. 
Comparison between (a) empty liposomes and (b) RF-482 
peptide associated liposomes Images taken at 50X 
magnification and 60kv HT.  
 
3.2 Cytotoxicity analysis 
Human epidermoid type-2 (HEP-2) cell were used for 
the assay. These HEP-2 cell were proliferated using 
minimum essential medium (MEM) having added 10 % 
fatal bovine serum (FBS) mM L-glutamine, 75 U/ml 
penicillin, 100 mg/ml kanamycin and 75 mg/ml 
streptomycin. Empty and functionalized liposomes as well 
as peptide RF-482 was tested for the cell toxicity by using 
dye MTT (3-(4, 5-dimethyl-thiazol-2-yl)-2, 5-diphenyl-
tetrazolium bromide). The reduction assay was performed 
using CellTiter 96® Non-Radioactive cell proliferation 
assay kit (Promega, Madison, WI, USA). 25,000 cells per 
well were seeded using MEM-10 (10% FBS). Two different 
concentrations of peptide RF-482, empty liposomes and 
functionalized liposomes were tested for the toxicity. Cell 
toxicity was assessed 72 hours post incubation. MTT assay 
was performed as per protocol provided (Promega, 
Madison, WI, USA). The absorbance was measured at 570 
nm using the plate reader (TECANTM, Morrisville, NC, 
USA). There was no toxicity observed with both the 
concentrations of all samples. For all the chosen 
concentration of all the samples, more than 80 % (n=3 ± 
SD) cell viability was observed after 72 hours of incubation 
(Figure 5). 
 
 
Figure 5 Screening of Peptide, Liposomes and peptide 
encapsulated against RSV. Plaques were counted and the 
mean plaque was count of for each sample was expressed as 
a percentage of the mean count of the control. (n=3 ±SD)  
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3.3 Qualitative analysis RSV inhibition 
Initially, the immunofluorescence imaging was used as 
a qualitative tool to study the RSV inhibition by liposomal 
system. the HEP-2 cells were incubated for 48 h with 
peptide RF-482, empty liposomes and functionalized 
liposomes, followed by fixing in paraformaldehyde-
glutaraldehyde and washing with buffer (1X PBS). An 
appropriate chamber from the 8 chambered slide was 
observed under the fluorescence microscope for the RSV 
activity.  
The obtained results confirm the effectiveness of the 
system to inhibit the RSV fusion to the HEP-2 cells (Figure 
6). Moreover, recently it was reported that the 
phosphatidylinositol (PI) inhibits the RSV as the PI binds 
the RSV with high affinity, inhibiting its fusion to the 
epithelial cells [10, 11]. Both PI and phosphocholine (PC) 
are deivatives of phospholipids , therefore the inhibition of 
RSV by DSPC liposomes alone can be expected.  
 
         
 
Figure 6 Fluorescence microscopy analysis. FITC (Green): 
RSV and DAPI (Blue): HEP-2 Cell nucleus.  In liposomes 
and RF-482 liposomes the blue colour represents survived 
cells and green colour represents presence of RSV. 
 
 
3.4 Quantitavie analysis of RSV inhibition 
The plaque assay is one of the most common and 
reliable methods of determination of viral/antiviral activity 
by counting plaques in the cell culture. Also, the plaque 
reduction assay is known as the optimum standard for 
antiviral activity analysis [12]. 
Liposomes with and without their conjugation product 
with the RSV fusion protein were tested against RSV 
infection to the HEP-2 cells. When these plaques were 
counted, it was observed that, in the presence of peptide 
RF-482/liposomes/peptide conjugated liposomes, the total 
number of plaques are significantly (p<0.005 ANOVA, post 
hoc-Dunnett’s multiple comparison test) less than in the 
absence of the same (Figure 7). 
 
 
 
 
Figure 7 Plaques were counted and the mean plaque was 
count of for each sample was expressed as a percentage of 
the mean count of the control. (n=3 ±SD). 
 
Having confirmation of viral inhibition from the 
microscopic as well as  from the plaque assay results, it was 
necessary to have another establised technique to validate 
the results obtained. Polymerase chain reaction (PCR), is 
one of the establised techniques available in the current 
biological research, employed for the quantification of the 
target sequence using real time, by detecting the number of 
amplicons generated at the end of every amplification cycle 
[13].  
qRT-PCR provides rapid and quantitative data for 
analysis of viral presence. However, before the 
amplification of cDNA via RT-PCR, the RNA was 
extracted from the samples and cDNA was synthesis 
edusing the superscript. After amplification, the obtained 
cycle threshold ‘Ct’ values were used as a tool for the 
comparison between the samples.  
Significant difference (p<0.005, ANOVA, post hoc-
Dunnett’s multiple comparison test) were observed between 
the Ct value of virus samples and samples having 
peptide/liposomes/conjugated liposomes (Figure 7).  
Whereas, there is no significant difference (p>0.05, t-test) 
observed between peptide/liposome alone as well as the 
conjugated liposomes. Although, the conjugated liposome 
samples displayed a slight trend for  higher Ct 
values,further suggesting more inhibition when used in 
combination (Figure 8).  
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 Figure 8 Screening of RSV-F gene amplicon dilution with 
water as negative control. Water represents blank or sample 
with no gene amplicon. Blue line: indicating the threshold 
of virus samplehas higher gene amplicon than the gene 
amplicon of standard 10^4. Comparison of viral gene 
amplicon (V) and Peptide (P1 & P2), Liposomes (L1 & 
L2), functionalized liposomes (LP1 & LP2). (n=3 ±SD) (* 
and ** in the figure represents p<0.05 and p<0.01 
respectively). 
 
 
4 CONCLUSION 
 
With the quest of finding an alternative carrier for 
delivering the anti-RSV peptide RF-482, a liposome 
formulation has been prepared and tested for the inhibition 
of RSV infection. The functionalization of liposomes was 
confirmed by various techniques including  dynamic light 
scattering (Figure 2), the surface charge, fluorescence 
imaging (Figure 3) and transmission electron microscopy 
(Figure 4). The cytotoxicity of various concentrations of 
these liposomes was tested by MTT assay and it was found 
that liposomes of two different concentrations of lipids with 
and without protein conjugation did not render any 
cytotoxic effect and molecular effect on the host HEP-2 
cells (Figure 5). The anti-RSV effect was then confirmed in 
plaque assay (Figure 7), immunofluorescence imaging 
(Figure 6) as well as in qRT-PCR (Figure 8). In plauqe 
assay significant difference was observed in number 
plaques observed for liposomes with and without protein 
(Figure 7). Similarly, in qRT-PCR, the cycle threshold (Ct) 
for liposomes of two different concentrations of lipids with 
and without protein conjugation was observed significantly 
higher (P <0.005, t-test) than the virus cycle threshold (Ct) 
(Figure 8). Overall, the results indicate that the liposome 
are a new potential candidate for delivery of anti-RSV 
peptide RF-482. However, exact mechanism of action of 
liposomes in inhibiting RSV need explorations foreseeing 
possibility of lipsomal vaccine for RSV infection.   
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